What allhat tells us about treating high-risk patients with hypertension and hyperlipidemia

Journal of Cardiovascular Nursing

Volumn 18, Issue 5, 2003, Pages 389-395

  Geraci, Therese S ^a   Geraci, Stephen A ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cardiovascular events; Hyperlipidemia treatment; Hypertension treatment; Review

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; RISK ASSESSMENT; RISK FACTORS;

EID: 0642379701     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200311000-00011     Document Type: Article

References (8)

1. Weber MA. Hypertension Medicine. Totowa, NJ: Humana Press, Inc.; 2001.
2. Davis BR, Cutler JA, Gordon DJ, et al, for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
3. The ALLHAT Officers and Coordinators, for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
4. The ALLHAT Officers and Coordinators, for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
5. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 4(6):1-12.
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on What ALLHAT Tells Us About Treating High-Risk Patients With Hypertension and Hyperlipidemia 395 Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
7. The ALLHAT Officers and Coordinators, for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomly assigned to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
8. Pasternak RC. The ALLHAT Lipid Lowering Trial-less is less. JAMA. 2002;288:3042-3044.